The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Size Of The Xerostomia Therapeutics Market In 2026 And How Much Will It Reach By 2030?
The xerostomia therapeutics market size has shown consistent expansion in recent years. It is projected to increase from $2.24 billion in 2025 to $2.35 billion in 2026, at a compound annual growth rate (CAGR) of 5.0%. This historical growth can be attributed to an aging population, the widespread use of xerogenic drugs, a rising prevalence of chronic diseases, enhanced dental awareness, and hospital-based symptom management.
The xerostomia therapeutics market size is projected to experience consistent expansion in the coming years, reaching $2.79 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. This anticipated growth during the forecast period is fueled by factors such as increased availability of OTC products, the growing prevalence of cancer therapy side effects, an uptick in self-medication practices, the widening reach of pharmacy networks, and a greater emphasis on treatments that enhance quality of life. Key developments expected within this period involve a rise in medication-induced dry mouth cases, increasing consumer demand for over-the-counter remedies, broader acceptance of artificial saliva solutions, the expansion of retail and mail-order pharmacy operations, and a sharper focus on managing oral symptoms.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp
Which Strategic Drivers Are Supporting The Xerostomia Therapeutics Market Development?
The increasing occurrence of chronic illnesses is anticipated to fuel the expansion of the xerostomia therapeutics market in the coming years. Chronic diseases are defined as enduring medical conditions that persist for many months or years, often progressing gradually and requiring continuous care. The primary cause of the growing incidence of chronic diseases is sedentary lifestyles, as a lack of regular physical activity contributes to health issues such as obesity, cardiovascular problems, diabetes, and other prolonged health conditions. Xerostomia therapeutics assist individuals with chronic diseases by relieving dry mouth symptoms and enhancing oral health, nutritional intake, and adherence to medication, all of which are vital aspects of managing long-term health conditions. For example, in June 2024, data from the National Health Service, a UK-based government department, revealed that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition characterized by elevated blood sugar levels, not yet severe enough to be classified as diabetes) in 2023, representing an 18% rise from 3,065,825 cases recorded in 2022. Consequently, the rising prevalence of chronic diseases is a key factor driving the growth of the xerostomia therapeutics market.
How Are Different Segment Groups Identified Within The Xerostomia Therapeutics Market?
The xerostomia therapeutics market covered in this report is segmented –
1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets
3) By End-User: Adult, Pediatric
Subsegments:
1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes
2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges
Which Trends Are Supporting The Evolution Of The Xerostomia Therapeutics Market?
Leading companies in the xerostomia therapeutics market are focusing on developing patient-friendly, non-invasive treatments, such as oral sprays that provide precise topical lubrication and protective barrier coverage across the mouth to relieve dry-mouth symptoms and support oral health. Oral sprays for xerostomia are formulations delivered as a fine mist directly onto the oral mucosa (tongue, palate, inner cheeks), forming either a hydrating film or a lipid-based coating to reduce moisture evaporation, enhance lubrication during chewing, swallowing, and speaking, and deliver longer duration relief in patients prone to dry mouth. For instance, in July 2023, K Pharmaceuticals, a US-based pharmaceutical company, launched Aquoral, a clinically-proven oral spray for managing xerostomia that utilizes patented Oxidized Glycerol Triesters (OGT) lipid technology to form a long-lasting protective barrier over the oral cavity, offering up to six hours of relief, enabling two quick sprays, and reducing the need for frequent reapplication compared to aqueous-based treatments.
Which Companies Are Engaged In The Xerostomia Therapeutics Market Environment?
Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd.
Access The Complete Xerostomia Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report
Which Region Contributes The Most To The Xerostomia Therapeutics Market?
North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Xerostomia Therapeutics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp
Browse Through More Reports Similar to the Global Xerostomia Therapeutics Market 2026, By The Business Research Company
Xerostomia Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report
Leukemia Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report
Mantle Cell Lymphoma Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model